KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ClearPoint Neuro (CLPT) EBIT (2018 - 2025)

ClearPoint Neuro (CLPT) has disclosed EBIT for 13 consecutive years, with -$7.0 million as the latest value for Q4 2025.

  • Quarterly EBIT fell 169.71% to -$7.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$24.2 million through Dec 2025, down 505.31% year-over-year, with the annual reading at -$24.2 million for FY2025, 505.31% down from the prior year.
  • EBIT hit -$7.0 million in Q4 2025 for ClearPoint Neuro, down from -$5.3 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $10.1 million in Q4 2024 to a low of -$7.1 million in Q2 2023.
  • Historically, EBIT has averaged -$4.0 million across 5 years, with a median of -$4.6 million in 2022.
  • Biggest five-year swings in EBIT: crashed 199.06% in 2021 and later skyrocketed 314.75% in 2024.
  • Year by year, EBIT stood at -$4.0 million in 2021, then fell by 12.23% to -$4.5 million in 2022, then fell by 5.3% to -$4.7 million in 2023, then surged by 314.75% to $10.1 million in 2024, then tumbled by 169.71% to -$7.0 million in 2025.
  • Business Quant data shows EBIT for CLPT at -$7.0 million in Q4 2025, -$5.3 million in Q3 2025, and -$5.7 million in Q2 2025.